DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,046 filers reported holding DANAHER CORPORATION in Q3 2016. The put-call ratio across all filers is 0.17 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,984,147 | +3.4% | 12,028 | 0.0% | 0.63% | +8.0% |
| Q2 2023 | $2,886,720 | -10.9% | 12,028 | -6.4% | 0.58% | -17.0% |
| Q1 2023 | $3,240,479 | -20.5% | 12,857 | -16.3% | 0.70% | -25.9% |
| Q4 2022 | $4,076,320 | +1.8% | 15,358 | -1.0% | 0.95% | -2.0% |
| Q3 2022 | $4,006,000 | +0.2% | 15,508 | -1.6% | 0.97% | +8.7% |
| Q2 2022 | $3,997,000 | -13.1% | 15,767 | +0.6% | 0.89% | +2.6% |
| Q1 2022 | $4,599,000 | -10.8% | 15,677 | 0.0% | 0.87% | +0.8% |
| Q4 2021 | $5,158,000 | +8.0% | 15,677 | -0.1% | 0.86% | -2.3% |
| Q3 2021 | $4,776,000 | +9.6% | 15,689 | -3.4% | 0.88% | +7.7% |
| Q2 2021 | $4,357,000 | +13.3% | 16,235 | -5.0% | 0.82% | +6.4% |
| Q1 2021 | $3,845,000 | -6.5% | 17,085 | -7.7% | 0.77% | -9.3% |
| Q4 2020 | $4,111,000 | -10.7% | 18,505 | -13.5% | 0.85% | -14.3% |
| Q3 2020 | $4,606,000 | +21.5% | 21,391 | -0.2% | 0.99% | +7.4% |
| Q2 2020 | $3,791,000 | +22.2% | 21,441 | -4.4% | 0.92% | -1.8% |
| Q1 2020 | $3,103,000 | -9.8% | 22,421 | 0.0% | 0.94% | +8.0% |
| Q4 2019 | $3,441,000 | +9.6% | 22,421 | +3.2% | 0.87% | +1.4% |
| Q3 2019 | $3,139,000 | -2.0% | 21,731 | -3.1% | 0.86% | -1.8% |
| Q2 2019 | $3,204,000 | +7.2% | 22,421 | -1.0% | 0.87% | +1.0% |
| Q1 2019 | $2,989,000 | +28.6% | 22,638 | +0.4% | 0.86% | +11.0% |
| Q4 2018 | $2,325,000 | -7.1% | 22,542 | -2.1% | 0.78% | +18.0% |
| Q3 2018 | $2,502,000 | +9.8% | 23,026 | -0.2% | 0.66% | +3.9% |
| Q2 2018 | $2,278,000 | -3.1% | 23,081 | -3.9% | 0.64% | -4.2% |
| Q1 2018 | $2,351,000 | +0.3% | 24,016 | -4.9% | 0.66% | +1.1% |
| Q4 2017 | $2,344,000 | -39.5% | 25,256 | -44.1% | 0.66% | -44.5% |
| Q3 2017 | $3,872,000 | -26.3% | 45,144 | -27.5% | 1.18% | -29.1% |
| Q2 2017 | $5,253,000 | -2.3% | 62,243 | -1.0% | 1.67% | -1.9% |
| Q1 2017 | $5,377,000 | +11.8% | 62,868 | +1.7% | 1.70% | +7.9% |
| Q4 2016 | $4,811,000 | +22.7% | 61,810 | +23.6% | 1.58% | +20.9% |
| Q3 2016 | $3,921,000 | -11.5% | 50,020 | +14.0% | 1.30% | -9.8% |
| Q2 2016 | $4,431,000 | +70.3% | 43,870 | +60.0% | 1.44% | +68.5% |
| Q1 2016 | $2,602,000 | +23.8% | 27,425 | +21.2% | 0.86% | +33.5% |
| Q4 2015 | $2,102,000 | – | 22,635 | – | 0.64% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |